Myles Wolf

This profile gathers the share dealings of Myles Wolf in Akebia Therapeutics, Inc., where the filings describe the role as board member. In total, 6 filings cover trades dated from 2 June 2021 to 17 June 2026.

None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.

On 22 June 2026 came the latest disclosure, a share grant in Akebia Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.